Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

[{"type":"image","alt":"Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.","displaySize":"","headline":null,"caption":"Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/e6d7d3838843c5425effa2e4ab62b44a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PtSbl1NYOkqDsA4Vg2yz2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e6d7d3838843c5425effa2e4ab62b44a","width":480,"height":320}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":327,"url":"https://media.zenfs.com/en/business-wire.com/5471a36faade42aaf55bcd71094c2c16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aPSBFdHvWpZFdjG21nBhtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5471a36faade42aaf55bcd71094c2c16","width":480,"height":327}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2481,"height":591,"url":"https://media.zenfs.com/en/business-wire.com/4b5d69dfe9818dd0423e58b86e5fafce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xIdKs8HHfAIWqiAyVH7iUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4b5d69dfe9818dd0423e58b86e5fafce","width":960,"height":229},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6frDn2tpNmbapKhnPydC1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4b5d69dfe9818dd0423e58b86e5fafce","width":1200,"height":286}}},{"type":"text","content":"JIANGSU, China & HEIDELBERG, Germany & CAMBRIDGE, Mass., July 08, 2025--(BUSINESS WIRE)--Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma"), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focusing on first- and best-...

More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A